Jackowski S, Murphy C M, Cronan J E, Rock C O
Department of Biochemistry, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.
J Biol Chem. 1989 May 5;264(13):7624-9.
The biochemical basis for the inhibition of fatty acid biosynthesis in Escherichia coli by the antibiotic thiolactomycin was investigated. A biochemical assay was developed to measure acetoacetyl-acyl carrier protein (ACP) synthase activity, a recently discovered third condensing enzyme from E. coli (Jackowski, S., and Rock, C.O. (1987) J. Biol. Chem. 262, 7927-7931). In contrast to the other two condensing enzymes in E. coli, acetoacetyl-ACP synthase (synthase III) condensed malonyl-ACP with acetyl-CoA, rather than with acetyl-ACP. The concentration dependence of thiolactomycin inhibition of fatty acid biosynthesis in vivo was the same as the inhibition of acetoacetyl-ACP synthase activity in vitro indicating that the two phenomena were related. A thiolactomycin-resistant mutant (strain CDM5) was isolated. The specific activity of acetoacetyl-ACP synthase in extracts from this mutant was 10-fold lower than in extracts from its thiolactomycin-sensitive parent resulting in a marked defect in the ability of strain CDM5 to incorporate acetyl-CoA into fatty acids in vitro. The residual acetoacetyl-ACP synthase activity in the resistant strain was refractory to thiolactomycin inhibition. In addition, acetyl-CoA:ACP transacylase activity in strain CDM5 was resistant to inactivation by thiolactomycin suggesting that the acetoacetyl-ACP synthase also catalyzes this transacylation reaction. These data point to acetoacetyl-ACP synthase as a target for thiolactomycin inhibition of bacterial fatty acid biosynthesis.
研究了抗生素硫代乳霉素抑制大肠杆菌脂肪酸生物合成的生化基础。开发了一种生化测定法来测量乙酰乙酰-酰基载体蛋白(ACP)合酶活性,这是一种最近从大肠杆菌中发现的第三种缩合酶(Jackowski,S.和Rock,C.O.(1987年)《生物化学杂志》262卷,7927 - 7931页)。与大肠杆菌中的其他两种缩合酶不同,乙酰乙酰-ACP合酶(合酶III)使丙二酸单酰-ACP与乙酰辅酶A缩合,而不是与乙酰-ACP缩合。硫代乳霉素在体内对脂肪酸生物合成抑制的浓度依赖性与在体外对乙酰乙酰-ACP合酶活性的抑制相同,表明这两种现象相关。分离出了一株对硫代乳霉素耐药的突变体(CDM5菌株)。该突变体提取物中乙酰乙酰-ACP合酶的比活性比其对硫代乳霉素敏感的亲本提取物低10倍,导致CDM5菌株在体外将乙酰辅酶A掺入脂肪酸的能力存在明显缺陷。耐药菌株中残留的乙酰乙酰-ACP合酶活性对硫代乳霉素的抑制具有抗性。此外,CDM5菌株中的乙酰辅酶A:ACP转酰基酶活性对硫代乳霉素的失活具有抗性,这表明乙酰乙酰-ACP合酶也催化这种转酰基反应。这些数据表明乙酰乙酰-ACP合酶是硫代乳霉素抑制细菌脂肪酸生物合成的靶点。